• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    Impact of Additive Manufacturing on the Orthopedic Industry

    Exiting a World of Pain

    Maintaining a Laser Focus

    Top Ten Design Rules for Orthopedic Device Development

    At the End of the Line—Packaging & Sterilization
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Oregon Surgical Institute to Implement Zimmer Biomet Signature Solutions Outpatient Program

    Game Ready Launches Full Leg Wrap for Compression, Cold, and Heat Therapies

    Study: Burn Wound Management Strategy Including Nanocrystalline Silver Dressings May Reduce Costs

    Stable Cartilage Tissue Successfully Cultivated from Stem Cells

    Zimmer Biomet Announces FDA Clearance of the Persona Trabecular Metal Tibia
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    Stable Cartilage Tissue Successfully Cultivated from Stem Cells

    Spikes of Graphene Can Kill Bacteria on Knee & Hip Implants

    Spineology Reveals 12-Month Outcomes for Interbody Fusion Clinical Trial

    CoreLink Launches Foundation 3D Printed Titanium Interbody Cages

    Augmented Reality App Could Aid Parkinson's Patients
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Stimulating the Natural Healing Process

    Targeting the Triple Aim

    Clinical Knowledge Key to Advancing Orthobiologics Technologies

    Minor Orthopedic Replacement Implants Global Market Exceeds $1.5 Billion

    Six Advantages of Machined Polymer Components over Metals
    Companies
    Categories
    Company Profiles
    White Papers
    Add New Company
    International Buyers Guide Companies
    Eagle Stainless Tube & Fabrication Inc.

    Rosler Metal Finishing

    Bihlermed

    Gauthier Biomedical Inc

    Paragon Medical
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Corporate Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Events
      • Industry Events
      • Live From Show Events
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Features

    Nature’s Way

    Still in search of that magic elixir, orthobiologics firms are producing natural-based alternatives for traumatic injuries.

    BIO4 Viable Bone Matrix retains all native bone activities involved in bone repair and regeneration. Image courtesy of Stryker Corp.
    BIO4 Viable Bone Matrix retains all native bone activities involved in bone repair and regeneration. Image courtesy of Stryker Corp.
    Related CONTENT
    • Stem Cell ‘Living Bandage’ for Knee Injuries Trialed in Humans
    • Fat-Derived Stem Cells Could Repair Shoulder Injuries
    • Stem Cell Technique Could Speed Bone Regeneration
    • Silver Ion-Coated Devices Could Fight MRSA While Regenerating Bone
    • FDA Clears Centric Medical's Metatarsal Hemi Implant System
    Michael Barbella, Managing Editor02.23.17
    Mike McDonald was a high school junior when the pain began.

    It wasn’t too debilitating at first—barely registering, really, as discomfort. There was a sharp twinge and odd clicking sensation in his shoulder, though neither could have lasted more than a second or two. McDonald, then 17, hardly had time to react before the pangs disappeared.

    Probably just a routine muscle spasm or something, McDonald thought to himself, attributing the cricks to his aggressions on the ice hockey rink.

    Ah, the naiveté of youth.

    McDonald couldn’t have known it then, but the twinge and “clicking sensation” he felt in his shoulder was the start of a Glenoid labrum tear—a rip in the cuff of cartilage circling the shoulder socket. Such injuries are common in certain rugged contact sports as well as those requiring repeated overhead movements (i.e., water polo, basketball, baseball, volleyball).

    After graduating high school, McDonald delayed college for a year to play in the Ontario Junior Hockey League. During that time, his shoulder pain worsened and he began dislocating the injured joint on a regular basis. “This began happening every few months, partly because I’m an aggressive player,” McDonald told Northwestern Lake Forest Hospital’s in-house magazine, healthreport. “Most goalies experience lower body impact, but I move my whole body around.”

    A Canadian doctor eventually diagnosed McDonald with a slight labrum tear but encouraged him to “play through it.” He did, suffering silently in the process, yet still performing well enough to be recruited by the Lake Forest College (Illinois) hockey team. The school’s grueling playing schedule, however, ultimately took a toll on McDonald’s shoulder, making it particularly susceptible to dislocation. Even so, McDonald insisted on playing through the pain—until his damaged joint slipped out of place during a game, costing his team a goal.

    McDonald’s coaches had seen enough at that point. They sent the young man for a medical evaluation with team physician Roger N. Chams, M.D., a top Chicago-area orthopedic surgeon. Chams diagnosed the Foresters goalie with torn ligaments and major bone loss in his shoulder socket—two potentially career-ending injuries. Chams gave McDonald a 65 percent chance of a full recovery with traditional surgery.

    “In the past, for patients with frequently dislocating shoulders—which is common among athletes—we would surgically reconstruct the shoulder or use a bone block and about 35 percent of them would fail,” Chams explained to healthreport.

    Rather than risk those odds, Chams used a new surgical technique based in human biologics to heal orthopedic conditions. Seeking to invoke Mother Nature’s mastery, Chams transplanted fresh bone and cartilage from a cadaver ankle directly into McDonald’s damaged shoulder socket in a procedure known as osteochondral allograft (OCA) reconstruction. This repair method relies upon the human body to work its magic, fusing the materials to the joint over a period of six months, during which time the patient receives physical therapy.

    Summoning the body’s natural healing process is becoming a preferred treatment option in orthopedics as longer- and harder-living patients demand longer-lasting, tougher solutions to age-related conditions and athletic injuries. These remedies are also preferred for their overall improved outcomes: The OCA repair method, for example, reduces the risk of recurrent joint instability and avoids many of the complications common in traditional procedures. It also might prevent the development of arthritis, according to experts.

    “The body is definitely more sophisticated than anybody realizes,” noted Alessandra Pavesio, senior vice president and chief science officer for Bioventus LLC, a Durham, N.C.-based orthobiologics developer formed in 2012 through a strategic venture between Essex Woodlands and Smith & Nephew plc.

    “What has become very apparent in this field is the truly powerful repair mechanisms that the body can trigger in a physiological fashion as opposed to adding a foreign material or introducing a drug that will inevitably hit the intended pathway but will also provide an imbalance to all the other pathways that are involved,” Pavesio continued. “In orthobiologics, you really have nature’s orchestra at your disposal as compared to just a single instrument. It’s very intuitive why an approach like this is going to be safe and in the long term, more effective. The time is ripe for these technologies to become available as I believe their adoption will greatly benefit patients.”

    Those benefits have long been proven, too: Clinical studies have shown that hyaluronic acid (a key component of articular cartilage) and platelet-rich plasma can reduce knee osteoarthritis pain, with the latter also effective at treating various other conditions like lateral epicondylitits, rotator cuff tears, and retro calcaneal bursitis.

    Likewise, allograft and autograft tissue are both tried-and-true architects of damaged anterior cruciate ligaments, though trial data tend to support the use of autograft tissue for young, active patients under age 25 and irradiated soft-tissue allograft for older, more sedentary folks. 

    Surgeons choosing autograft ACL repair often use the patient’s own hamstring to rebuild the injured ligament. Autograft is considered a more natural approach to ACL reconstruction and other orthopedic procedures since it uses the patient’s own tissue, thus minimizing the risk of rejection. But this method is not without its shortcomings, as patients often experience increased postoperative pain from the second surgical (autograft) site, and potentially require longer periods of rehabilitation.

    Allografts, on the other hand, eliminate the need for a second procedure, thereby reducing operating room time and expediting recovery. Yet this approach isn’t foolproof, either: Donated tissue is usually more expensive, is not always available, and is prone to biological rejection. Moreover, allografts may not incorporate themselves properly into the recipient’s own body function, and may take longer to connect with an existing joint.

    Such autograft- and allograft-related limitations are helping to fuel growth in the global orthobiologics market and spawning advancements in bone graft technology and regenerative therapies.

    Among the newest innovations in bone graft material is the i-FACTOR Peptide Enhanced Bone Graft from Westminster, Colo.-based Cerapedics Inc. The graft leverages the biological activity of a synthetically derived 15-amino acid peptide (P-15) to support bone growth through cell attachment and activation, according to the company. It is approved for use as a substitute for autologous bone in anterior cervical discectomy and fusion procedures.

    Northwestern University scientists, meanwhile, are on the verge of revolutionizing the future of bone grafts and reconstructive surgery with the development of “hyperelastic bone” (HB), a 3D-printed synthetic material made mostly from hydroxyapatite. Mixed with a polymer to add flexibility, HB can either be implanted under the skin to serve as a scaffold for new bone growth or used to replace lost bone. 

    Researchers tested the hyperelastic bone in real surgical situations, using it to fuse together two spinal vertebrae in a rat, and replace a section of unhealthy rhesus monkey skull. In both cases, the implant fully integrated with the host tissue, encouraging the growth of blood vessels and even some new bone.
    Albeit promising, HB has yet to be tested on humans.

    Complimenting these potentially game-changing strides in bone graft technology are harvesting and delivery systems innovations like those developed by NovaBone Products LLC, TranS1, and Stryker Corp.

    NovaBone’s MacroFORM MIS Delivery System is designed for use in minimally invasive procedures, allowing surgeons to directly deliver bone marrow aspirate to a graft housed in a closed, ready-to-use cannula. The system allows physicians to precisely deliver bone grafting material to surgical sites that are not readily accessible.

    TranS1’s Capital Bone Graft Harvester, on the other hand, is designed to collect reproducible autograft material from the iliac crest while its Pylon Graft Delivery tool is designed for posterolateral fixation. The Pylon deposits bone graft material through the same incision as the posterior fixation and can be used in conjunction with posterior fixation, interbody fusion, and laminectomy.

    TranS1’s Capital Harvester and Pylon Delivery tool made their market debut last fall around the same time Stryker released its LITe BIO Delivery System, a tool that gives surgeons a single-handed method to deliver “any type of autograft, allograft, or synthetic bone graft material without obstructing visibility.” The patented system can be used for any type of spinal fusion procedure, including minimally invasive surgeries. Its low-profile design allows visibility through a decompression tube without obstructing the view, and disposable cannula can deliver up to 5cc of bone graft at one time.

    “A significant need in the market is improving the delivery of bone graft to spinal surgery sites,” said John Mayor, vice president of global marketing for Stryker’s Spine Division. “The LITe BIO Delivery System provides tactile, visual, and audible confirmation of bone graft delivery, and the mallet-free system is designed to eliminate the impaction of bone graft.”

    Indeed, delivery accuracy is as crucial to bone repair as the reconstructive technique itself. In recent years, the bone graft substitute market has been shifting away from allograft and growth factors usage to more natural remedies like those engineered by Kuros Biosciences A.G., a Swiss developer of tissue repair and regeneration products. Amidst the firm’s most advanced technologies are KUR-111 and KUR-113, both of which are designed to help heal fractures. KUR-111 consists of a natural matrix (fibrin), a targeted bone growth factor and a structural ceramic component that form a paste for direct insertion into fracture voids. The material can be left to polymerize in situ to adopt the defect’s shape and form an ideal space-filling graft substitute that resists compression while providing optimal biological support for healing.

    Kuros has completed a Phase IIb clinical trial assessing KUR-111’s potential to treat tibial plateau fractures requiring fixation and grafting. Tibial plateau fractures are often complex and usually caused by high-energy trauma such as automobile or industrial accidents, or sports injuries.

    KUR-113 is also applied directly into fracture voids, but forms a gel-like material that infiltrates fracture sites without disturbing the surrounding tissue. Like its sister product, this matrix aims to improve fracture healing.

    “The regenerative mechanisms of the body are extremely complex,” Pavesio said. “To date, the standard of care in just about any [orthopedic] surgery remains an autologous graft because it is very, very hard to synthetically reproduce a tissue, considering all the complexity that goes into it. That’s why allografts are so widely used and why they have clinical merit. We’re not reproducing the complexity involved or the shared pathways, we’re just implanting what Mother Nature has already done. When you’re trying to duplicate something, you’re simplifying it to the point where you risk changing its subleties. It’s extremely complicated to duplicate what we have. I think our best bet is to find ways to identify therapeutic strategies that will trigger the intrinsic self-repair mechanism of the tissue for example, so we can utilize orthobiologic approaches to attract resident cells to injured tissue and do the work. What we can do is provide a substrate for these cells to work as well as a signal for the proper molecules to come and do their magic.’ ”

    One of the most gifted famuli seems to be stem cells, primitive organisms with an amazing capacity for self-renewal and specialization. These cells play a leading role in the body’s healing process and have been used for decades to treat various conditions including leukemia, sickle cell anemia, lymphoma, and other blood diseases.

    Stem cells have more recently been used in the orthopedic industry to treat arthritis, bone fractures and non-unions, degenerative vertebral discs, damaged cartilage, and torn tendons/ligaments. Most procedures are still experimental, according to experts, but a growing number of therapies are being offered by clinics touting clinically unproven results. Concerns over the spread of these untested treatments has prompted the U.S. Food and Drug Administration to re-examine its guidelines on human-derived therapies (see sidebar). 

    The adult stem cells considered the most propitious for orthopedic applications are mesenchymal cells, which have been isolated from various tissue sources including bone marrow, adipose tissue, periosteum, and the synovial lining.

    “By taking advantage of new scientific insights on how the body repairs, regenerates, and heals tissue that results from trauma or age, new therapies are being pioneered that focus on the repair of joints versus replacement of joints,” noted Andrew McGillicuddy, CEO of Endocellutions Inc., a Marshfield, Mass.-based developer of regenerative medicine technology. “At the forefront of these initiatives is the use of stem cells from bone marrow. The natural response to any damaged tissue is to mobilize stem cells from the marrow space to the defect site. By sourcing marrow and transplanting it to the area of trauma, the clinician is exactly mimicking and supplementing the body’s natural response to injury.”

    Endocellutions’ mimicry of Mother Nature is channeled through a bone marrow device called MarrowCellution. The tool enables clinicians to aspirate several small volumes of concentrated marrow across a broad geography of marrow space, the company claims.

    MarrowCellution precisely repositions the aspiration system to a new location in the marrow after each mL collected, but never uses more than one entry point. The product is designed to draw marrow from side ports while avoiding dilution with the peripheral blood that often pools below the tip as the aspiration needle is withdrawn.

    The proprietary device optimizes stem cell yields by minimizing peripheral blood contamination. “Using this technology, with a simple marrow aspiration of 10 mL, a clinician is able to get 300 percent more stem cells than if 60 mL was drawn and concentrated by a centrifuge down to 10 mL,” McGillicuddy explained. “Stem cells are what heal tissue.”

    Stryker’s tissue-healing technology also involves the use of mesenchymal stem cells. Its BIO4 Viable Bone Matrix, developed by Osiris Therapeutics Inc. (the companies partnered in late 2014 to expand Stryker’s biologics portfolio), is a viable bone matrix containing endogenous bone-forming cells designed to facilitate bone repair and regeneration. It aims to provide a safe alternative to bone autograft and minimize the potential for harvest site co-morbidities.

    “Stryker’s BIO4 Viable Bone Matrix retains viable cells and retains all native bone activities involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic, and angiogenic,” Mayor said. “The trend away from growth factors is opening opportunities to meet surgeons’ needs and preferences with a variety of other options. These technologies include non- proprietary allograft chips, synthetics, demineralized bone matrix, and stem cells. Each has a different function or mechanism of action. Some act primarily as scaffolds, as in the case of allograft chips and synthetics, and others have signals that stimulate bone growth in the body, such as demineralized bone matrix and stem cells. The market is looking for alternatives that provide an active environment to stimulate bone growth in a safe way.”  

    Taming Medicine’s ‘Wild West’
    All they want is control of their destinies. Nothing more, nothing less.

    In truth, Georgianna Crocker and Ted Gradel are fighting for the right to medically use their own stem cells without government interference. “When I look at that little vial, the little sliver of SVF—stromal vascular fraction—that is sitting at the bottom of that test tube, those came out of my body and those are my cells,” Gradel told a U.S. Food and Drug Administration (FDA) panel last fall. “I don’t really care...if they have been manipulated either minimally or maximally, I feel like I should have the right to have those cells injected back into my own body...That decision should rest between me and my physician.”

    Perhaps it should, but concerns over the growing number of U.S. clinics dispensing untested—and in many cases, unproven—stem cell treatment has prompted the FDA to rethink its rules on human tissue-derived therapies. The agency held a two-day hearing last September on new guidance that clarifies existing regulations on stem cell remedies.

    Heralded for their ability to multiply and morph into any type of biological cell, stem cells have been used for decades (with the FDA’s blessing) to treat certain blood disorders and leukemia. Their use has become more widespread in recent years with endorsements from high-profile athletes like Bartolo Colon and Peyton Manning, both of whom used stem cell therapies to heal bulging discs, damaged ligaments, and a torn rotator cuff. Nevertheless, stem cell science is still evolving and proving difficult to understand, as the cells themselves can sometimes be unmanageable and harmful to living organisms.

    FDA approval is currently not required for stem cell therapies as long as the recruited cells are not significantly altered, are used in a similar way to their original purpose, and are derived from a patient’s own stem cell bank. The new guidelines, however, add a few more stipulations for sidestepping regulators: Stem cell function must be identical in both the donor and recipient; treatment cells cannot affect the recipient’s entire body; and manufacturers can only manipulate the cells “minimally.” The revised rules also specify the chemicals manufacturers can use to treat cells and prevent disease transmission.

    FDA officials insist the revamped guidelines are meant to clarify existing regulations, but stem cell advocates fret the new rules will deny patients a viable treatment alternative for debilitating illnesses. For Crocker, the agency’s “hands-off” approach to stem cell regulation has been a blessing—the fat cells harvested from her body two years ago virtually eradicated the rheumatoid arthritis that had ravaged her joints for nearly a decade. During last fall’s hearing, she recounted her journey from arthritis victim to victor, touting her negligible C-reactive protein (inflammation marker) levels and normal white blood cell counts. The turnaround in Crocker’s health has been so dramatic, in fact, that she ran a half-marathon last July.

    “...I ask that you strengthen my rights as a patient to be treated with my own stem cells and to accelerate this availability of treatment that is safe and effective, and to please not classify my own cells as a drug,” Crocker appealed to FDA officials. “They are my own cells and I ask that you respectfully treat them that way.”

    The FDA’s intention, of course, is not one of disrespect but rather safety. Agency administrators object to testaments like Crocker’s that proclaim stem cell therapy “safe and effective,” since its safety and efficacy are still largely unproven. Despite promising preliminary evidence, scientific studies thus far “have not reliably demonstrated the effectiveness of stem cell treatments even in some of the most systematically studied conditions such as heart failure and graft-versus-host disease,” FDA bigwigs wrote in a New England Journal of Medicine article last November. This lack of evidence is worrisome.”

    Even more troubling to FDA executives is the proliferation of unregulated stem cell treatments by hundreds of U.S. clinics that lack the scientific evidence to support their work. Doctors, researchers, and nurses at the FDA’s panel hearing implored the agency to increase its oversight to better protect patients and control an industry that some experts have likened to the Wild West.

    “The out-of-control marketplace for stem cell interventions needs effective regulatory oversight,” Leigh Turner, an associate professor at the University of Minnesota Center for Bioethics (Minneapolis), declared to the FDA’s Biologics Evaluation and Research Center panel. “I therefore hope the draft guidances are more than stage props and this hearing is more than public theater. When patient safety and public health are at stake, the FDA must do more than function as a paper tiger. It is time for action.”  — M.B. 
    Related Searches
    • knee osteoarthritis
    • muscle
    • minimally invasive
    • acl repair
    Suggested For You
    Implant Disruption Implant Disruption
    Injured Bones Repaired with Stem Cells, Gene Therapy, and Ultrasound Injured Bones Repaired with Stem Cells, Gene Therapy, and Ultrasound
    Forming New Intervertebral Discs with Stem Cells Forming New Intervertebral Discs with Stem Cells
    3D Bioprinter Uses Stem Cell Ink to Churn Out Cartilage 3D Bioprinter Uses Stem Cell Ink to Churn Out Cartilage
    Stem Cells Edited to Fight Arthritis Stem Cells Edited to Fight Arthritis
    AANS: FDA Clears joimax Endovapor 2 Multi Radio Frequency System AANS: FDA Clears joimax Endovapor 2 Multi Radio Frequency System
    Stem Cell Innovation Regrows Rotator Cuffs Stem Cell Innovation Regrows Rotator Cuffs
    3D Bioprinted Human Cartilage Cells Can Be Implanted 3D Bioprinted Human Cartilage Cells Can Be Implanted
    Testing Your Patience Testing Your Patience
    AAOS: Bioventus to Invest in New Clinical Research for EXOGEN AAOS: Bioventus to Invest in New Clinical Research for EXOGEN
    FDA Clears Amend Surgical FDA Clears Amend Surgical's NanoFUSE BA Synthetic Bone Graft
    VEXIM Completes Enrollment in Clinical Trial VEXIM Completes Enrollment in Clinical Trial
    Let’s Keep It Clean, Folks Let’s Keep It Clean, Folks
    Surgical Sophistication Surgical Sophistication
    Smart Outsourcing:  Hiring the Team to Get Your Class III Device to Market Smart Outsourcing: Hiring the Team to Get Your Class III Device to Market

    Related Features

    • 3-D Printing/Additive Mfg.
      Impact of Additive Manufacturing on the Orthopedic Industry

      Impact of Additive Manufacturing on the Orthopedic Industry

      Direct metal printing enables a number of benefits to enhance today’s bone replacement offerings.
      Hannelore Eykens and Ruben Wauthle, Ph.D., 3D Systems—Healthcare 03.21.18

    • Spine/Neurology
      Exiting a World of Pain

      Exiting a World of Pain

      Groundbreaking neurostimulation technologies could help mitigate opioid abuse among chronic pain patients.
      Sam Brusco, Associate Editor 03.21.18

    • Coatings/Surface Modification | Laser Processing | Machining & Tooling
      Maintaining a Laser Focus

      Maintaining a Laser Focus

      Laser machining and processing advance to enable more applications for orthopedic device manufacturers.
      Mark Crawford, Contributing Writer 03.21.18


    • Design | Research & Development
      Top Ten Design Rules for Orthopedic Device Development

      Top Ten Design Rules for Orthopedic Device Development

      While every engineer draws from their own experiences, one designer shares his top ten guidelines for every project.
      John Pepper, PE, Principal Engineer, Nextremity Solutions 02.12.18

    • Packaging & Sterilization
      At the End of the Line—Packaging & Sterilization

      At the End of the Line—Packaging & Sterilization

      In order to ensure a smooth transition from manufacturing to market, packaging and sterilization should be considered early.
      Mark Crawford, Contributing Writer 02.12.18

    • Biologics
      Biological Building Blocks

      Biological Building Blocks

      Manufacturers and researchers increasingly are using Mother Nature as a model to devise new healing technologies.
      Michael Barbella, Managing Editor 02.12.18


    • Reshaping the Tools of the Trade—Instrument Manufacturing

      Reshaping the Tools of the Trade—Instrument Manufacturing

      Surgical instrument manufacturers must be aware of rising single-use instrument adoption and surgeon ergonomics.
      Sam Brusco, Associate Editor 02.12.18

    • 3-D Printing/Additive Mfg. | Design | Prototyping | Research & Development
      Bringing Conceptual Design to Life Through Prototypes

      Bringing Conceptual Design to Life Through Prototypes

      OEMs seek to address speed to market and manufacturability considerations through prototype solutions.
      Mark Crawford, Contributing Writer 11.21.17

    • Physician, Reinvent Thyself: A Look at Surgeon Inventors

      Physician, Reinvent Thyself: A Look at Surgeon Inventors

      Follow the stories of two orthopedic surgeons who realized unmet clinical needs and brought them to life.
      Sam Brusco, Associate Editor 11.21.17


    • Medtech Mettle: A Year in Review

      Medtech Mettle: A Year in Review

      Steely resolve and resolutions helped the orthopedic industry survive a politically tumultuous year.
      Michael Barbella, Managing Editor 11.21.17

    • Large Joint
      Patent Insight into Knee Replacement Prosthetics

      Patent Insight into Knee Replacement Prosthetics

      Established leaders are primarily focused on traditional solutions while newer firms look to customization.
      Justin Wen, Intellectual Property Consultant, Global Prior Art 10.02.17

    • Laser Processing | Machining & Tooling
      Machining Medicine: Insights into Precision and Laser Machining Demands

      Machining Medicine: Insights into Precision and Laser Machining Demands

      New capabilities and functionality keep precision and laser machining relevant for orthopedic technologies.
      Mark Crawford, Contributing Writer 10.02.17

    • 3-D Printing/Additive Mfg. | Contract Manufacturing | Design | Materials | Prototyping | Research & Development
      Back to the Drawing Board: Designing Orthopedic Devices

      Back to the Drawing Board: Designing Orthopedic Devices

      Cost pressures, regulatory hurdles, and novel manufacturing methods challenge orthopedic technology designers' creativity.
      Sam Brusco, Associate Editor 10.02.17

    • 3-D Printing/Additive Mfg. | Materials | Spine/Neurology
      Distinguished Support: A Review of Spinal Orthopedic Technologies

      Distinguished Support: A Review of Spinal Orthopedic Technologies

      Success and market share in the slow-growing, crowded spinal sector are dependent upon differentiated solutions.
      Michael Barbella, Managing Editor 10.02.17

    • Biologics | Bracing/Prosthetics | Extremities | Imaging | Instruments | Large Joint | Spine/Neurology | Trauma/Sports
      Top 10 Global Orthopedic Device Firms

      Top 10 Global Orthopedic Device Firms

      This year’s Top 10 company report illuminated a number of trends within the orthopedic market.
      Sean Fenske, Editor; Michael Barbella, Managing Editor; Sam Brusco, Associate Editor 08.15.17


    Breaking News
    • Stradis Healthcare Announces New Medical Device Packaging Division Director
    • Oregon Surgical Institute to Implement Zimmer Biomet Signature Solutions Outpatient Program
    • Game Ready Launches Full Leg Wrap for Compression, Cold, and Heat Therapies
    • Study: Burn Wound Management Strategy Including Nanocrystalline Silver Dressings May Reduce Costs
    • Stable Cartilage Tissue Successfully Cultivated from Stem Cells
    View Breaking News >
    CURRENT ISSUE

    March/April 2018

    • Impact of Additive Manufacturing on the Orthopedic Industry
    • Exiting a World of Pain
    • Maintaining a Laser Focus
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.